• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.原始抗原决定簇决定了人巨细胞病毒糖蛋白 B/MF59 疫苗在血清阳性受者中引发的免疫反应谱。
J Infect Dis. 2019 Jun 19;220(2):228-232. doi: 10.1093/infdis/jiz089.
2
Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.针对人巨细胞病毒糖蛋白 B 疫苗与 MF59 的表位特异性体液反应：抗 AD2 水平与预防病毒血症相关。
J Infect Dis. 2018 May 25;217(12):1907-1917. doi: 10.1093/infdis/jiy102.
3
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.人巨细胞病毒糖蛋白 B 核苷修饰 mRNA 疫苗诱导的抗体应答比 MF59 佐剂 gB 蛋白免疫具有更高的持久性和更广的谱。
J Virol. 2020 Apr 16;94(9). doi: 10.1128/JVI.00186-20.
4
HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.巨细胞病毒糖蛋白 B 亚单位疫苗通过非中和抗体效应功能介导的功效。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. doi: 10.1073/pnas.1800177115. Epub 2018 Apr 30.
5
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.糖蛋白 B 疫苗接种可预防巨细胞病毒血症，而中和抗体对此并无影响。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.
6
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.人巨细胞病毒 mRNA-1647 疫苗候选物比 gB/MF59 疫苗诱导更强和更广泛的中和及抗体依赖性细胞细胞毒性反应。
J Infect Dis. 2024 Aug 16;230(2):455-466. doi: 10.1093/infdis/jiad593.
7
A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.复制缺陷型人巨细胞病毒疫苗可诱导类似于自然感染的体液免疫应答。
J Virol. 2019 Nov 13;93(23). doi: 10.1128/JVI.00747-19. Print 2019 Dec 1.
8
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.IgA 与糖蛋白 B 的 AD-2 表位结合并中和人巨细胞病毒。
Immunology. 2021 Mar;162(3):314-327. doi: 10.1111/imm.13286. Epub 2020 Dec 13.
9
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.接种巨细胞病毒 gB-MF59 疫苗的血清阴性患者在移植后早期具有针对 gB 的中和抗体反应的证据。
EBioMedicine. 2019 Dec;50:45-54. doi: 10.1016/j.ebiom.2019.11.005. Epub 2019 Nov 15.
10
Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.血清阴性糖蛋白 B 疫苗接种者获得的人类巨细胞病毒变异株的宿主内动态。
J Virol. 2019 Feb 19;93(5). doi: 10.1128/JVI.01695-18. Print 2019 Mar 1.

引用本文的文献

1
Immune imprinting and next-generation coronavirus vaccines.免疫印记与下一代冠状病毒疫苗。
Nat Microbiol. 2023 Nov;8(11):1971-1985. doi: 10.1038/s41564-023-01505-9. Epub 2023 Nov 6.
2
Mind the Gap-A Perspective on Strategies for Protecting against Bacterial Infections during the Period from Infection to Eradication.注意差距——关于感染至根除期间预防细菌感染策略的观点
Microorganisms. 2023 Jun 29;11(7):1701. doi: 10.3390/microorganisms11071701.
3
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.一种依赖温度的病毒结合测定法揭示了人巨细胞病毒 gB 疫苗接种者血清中存在中和抗体。
J Gen Virol. 2023 Jun;104(6). doi: 10.1099/jgv.0.001860.
4
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity.抗原进化和原始抗原致敏对 SARS-CoV-2 免疫的影响。
J Clin Invest. 2023 Jan 3;133(1):e162192. doi: 10.1172/JCI162192.
5
Analysis and Fine Specificity of the HCMV-Specific Cell-Free and Cell-Associated Antibody-Dependent Cellular Phagocytosis (ADCP) Responses in Lung Transplant Recipients.肺移植受者中巨细胞病毒特异性游离和细胞相关抗体依赖的细胞吞噬（ADCP）反应的分析及精细特异性。
Int J Mol Sci. 2021 Jul 30;22(15):8206. doi: 10.3390/ijms22158206.
6
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.基于肽微阵列的 SARS-CoV-2 抗体反应分析鉴定出具有潜在诊断测试开发价值的独特表位。
Eur J Immunol. 2021 Jul;51(7):1839-1849. doi: 10.1002/eji.202049101. Epub 2021 May 7.
7
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.IgA 与糖蛋白 B 的 AD-2 表位结合并中和人巨细胞病毒。
Immunology. 2021 Mar;162(3):314-327. doi: 10.1111/imm.13286. Epub 2020 Dec 13.
8
Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults.蛋白质组学分析疟疾疫苗研究揭示了坦桑尼亚成年人个性化的体液免疫特征。
Elife. 2020 Jul 14;9:e53080. doi: 10.7554/eLife.53080.
9
Human Cytomegalovirus Infection in Women With Preexisting Immunity: Sources of Infection and Mechanisms of Infection in the Presence of Antiviral Immunity.人类巨细胞病毒感染在具有预先存在免疫力的女性中：存在抗病毒免疫时感染的来源和机制。
J Infect Dis. 2020 Mar 5;221(Suppl 1):S1-S8. doi: 10.1093/infdis/jiz464.
10
Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.用于开发抗人巨细胞病毒疫苗的病毒样颗粒和纳米颗粒。
Viruses. 2019 Dec 28;12(1):35. doi: 10.3390/v12010035.

本文引用的文献

1
HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.巨细胞病毒糖蛋白 B 亚单位疫苗通过非中和抗体效应功能介导的功效。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272. doi: 10.1073/pnas.1800177115. Epub 2018 Apr 30.
2
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.糖蛋白 B 疫苗接种可预防巨细胞病毒血症，而中和抗体对此并无影响。
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23.
3
Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.针对人巨细胞病毒糖蛋白 B 疫苗与 MF59 的表位特异性体液反应：抗 AD2 水平与预防病毒血症相关。
J Infect Dis. 2018 May 25;217(12):1907-1917. doi: 10.1093/infdis/jiy102.
4
Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient.界定器官捐献者向受者传播人巨细胞病毒中断的标准。
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1958. Epub 2017 Nov 17.
5
The Doctrine of Original Antigenic Sin: Separating Good From Evil.原始抗原罪学说：区分善恶
J Infect Dis. 2017 Jun 15;215(12):1782-1788. doi: 10.1093/infdis/jix173.
6
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.巨细胞病毒糖蛋白B（gB）疫苗在青春期女孩中的安全性和有效性：一项随机临床试验。
Vaccine. 2016 Jan 12;34(3):313-9. doi: 10.1016/j.vaccine.2015.11.056. Epub 2015 Dec 2.
7
The pathogenesis of human cytomegalovirus.人类巨细胞病毒的发病机制。
J Pathol. 2015 Jan;235(2):288-97. doi: 10.1002/path.4437.
8
Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. preemptive 治疗管理下实体器官移植受者巨细胞病毒复制动力学。
Am J Transplant. 2012 Sep;12(9):2457-64. doi: 10.1111/j.1600-6143.2012.04087.x. Epub 2012 May 17.
9
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.用 MF59 佐剂的巨细胞病毒糖蛋白 B 疫苗在移植受者中的效果：一项 2 期随机安慰剂对照试验。
Lancet. 2011 Apr 9;377(9773):1256-63. doi: 10.1016/S0140-6736(11)60136-0.
10
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.巨细胞病毒血清流行率及与感染相关的人口统计学特征综述。
Rev Med Virol. 2010 Jul;20(4):202-13. doi: 10.1002/rmv.655.

原始抗原决定簇决定了人巨细胞病毒糖蛋白 B/MF59 疫苗在血清阳性受者中引发的免疫反应谱。

Original Antigenic Sin Shapes the Immunological Repertoire Evoked by Human Cytomegalovirus Glycoprotein B/MF59 Vaccine in Seropositive Recipients.

机构信息

Institute for Immunity and Transplantation, University College London, United Kingdom.

Clinical and Experimental Medicine, Brighton and Sussex Medical School, United Kingdom.

出版信息

J Infect Dis. 2019 Jun 19;220(2):228-232. doi: 10.1093/infdis/jiz089.

DOI:10.1093/infdis/jiz089
PMID:30815685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6581893/
Abstract

A human cytomegalovirus (HCMV) vaccine is urgently needed to protect against primary infection and enhance existing immunity in HCMV-infected individuals (HCMV+). Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients prior to transplant, we investigated the composition of the immune response. Vaccination boosted preexisting humoral responses in our HCMV+ cohort but did not promote de novo responses against novel linear epitopes. This suggests that prior natural infection has a profound effect on shaping the antibody repertoire and subsequent response to vaccination ("original antigenic sin"). Thus, vaccination of HCMV+ may require strategies of epitope presentation distinct from those intended to prevent primary infection.

摘要

人巨细胞病毒 (HCMV) 疫苗的研发迫在眉睫，其目的是预防原发性感染并增强已感染 HCMV 个体（HCMV+）的现有免疫力。本研究使用 HCMV+糖蛋白 B/MF59 疫苗受种者移植前的血清，调查了免疫反应的组成。疫苗接种增强了我们的 HCMV+队列中预先存在的体液反应，但并未促进针对新线性表位的新反应。这表明先前的自然感染对塑造抗体库以及随后对疫苗接种的反应（“原始抗原性偏倚”）有深远影响。因此，HCMV+的疫苗接种可能需要与预防原发性感染不同的表位呈递策略。